Haohai Biological Technology's controlled subsidiary, Henan Saimeishi Biotechnology Co., Ltd., has obtained the Medical Device Registration Certificate of the People's Republic of China from the National Medical Products Administration for its trifocal toric intraocular lens. The product is indicated for vision correction in adult cataract patients with corneal astigmatism who have no natural lens, aiming to correct corneal astigmatism while improving near, intermediate, and distance vision and reducing dependence on glasses. In the first quarter of 2026, Haohai Biological Technology achieved revenue of 571 million yuan and net profit attributable to the parent company of 73.56 million yuan.
Shanghai Haohai Biological Tech CoSubsidiary received medical device registration for trifocal toric intraocular lens, a new product approval.
Obtained medical device registration certificate for its trifocal toric intraocular lens.
